Interleukin-6-controlled, mesenchymal stem cell-based sodium/iodide symporter gene therapy improves survival of glioblastoma-bearing mice

New treatment strategies are urgently needed for glioblastoma (GBM)—a tumor resistant to standard-of-care treatment with a high risk of recurrence and extremely poor prognosis. Based on their intrinsic tumor tropism, adoptively applied mesenchymal stem cells (MSCs) can be harnessed to deliver the th...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitzberger, Carolin, Shehzad, Khuram, Morath, Volker, Spellerberg, Rebekka, Ranke, Julius, Steiger, Katja, Kälin, Roland E., Multhoff, Gabriele, Eiber, Matthias, Schilling, Franz, Glass, Rainer, Weber, Wolfgang A., Wagner, Ernst, Nelson, Peter J., Spitzweg, Christine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493263/
https://www.ncbi.nlm.nih.gov/pubmed/37701849
http://dx.doi.org/10.1016/j.omto.2023.08.004

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10493263/
https://www.ncbi.nlm.nih.gov/pubmed/37701849
http://dx.doi.org/10.1016/j.omto.2023.08.004

Ejemplares similares